<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; NovaBay Pharmaceuticals Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/novabay-pharmaceuticals-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(ACL) Alcon &#8211; Solid Growth Across All Segments &#8211; Novartis Wants to Acquire Alcon</title>
		<link>http://www.stockbloghub.com/2010/03/03/acl-alcon-solid-growth-across-all-segments-novartis-wants-to-acquire-alcon/29521</link>
		<comments>http://www.stockbloghub.com/2010/03/03/acl-alcon-solid-growth-across-all-segments-novartis-wants-to-acquire-alcon/29521#comments</comments>
		<pubDate>Wed, 03 Mar 2010 22:00:37 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[NBY]]></category>
		<category><![CDATA[NovaBay Pharmaceuticals Inc]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=29521</guid>
		<description><![CDATA[Alcon (ACL) is delivering solid growth across all business segments and pays a dividend yield of 2.3%. Company Description Alcon is one of the world&#8217;s leading suppliers of eye care products. The company has three operating segments: Pharmaceutical, which develops glaucoma products, ocular anti-infectives, and ocular allergy products, Surgical, which serves cataract market with its Infiniti vision system and AcrySof intraocular lenses, and Consumer Eye Care, which sells contact lens care products, artificial tears, and ocular vitamins. Growth Story Alcon&#8217;s pharmaceutical and surgical segments continue to deliver steady revenue growth. In the fourth quarter, U.S. sales were up 10% thanks to improving demand for prescriptions and cataract procedures. International organic sales, driven by emerging markets, were up 7%. In addition, Alcon&#8217;s acquisition strategy should help drive long-term growth. The company ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/03/acl-alcon-solid-growth-across-all-segments-novartis-wants-to-acquire-alcon/29521/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

